Transapical Mitral Valve Replacement: 1-Year Results of the Real-World Tendyne European Experience Registry
Standard
Transapical Mitral Valve Replacement: 1-Year Results of the Real-World Tendyne European Experience Registry. / Hell, Michaela M; Wild, Mirjam G; Baldus, Stephan; Rudolph, Tanja; Treede, Hendrik; Petronio, Anna Sonia; Modine, Thomas; Andreas, Martin; Coisne, Augustin; Duncan, Alison; Franco, Luis Nombela; Praz, Fabien; Ruge, Hendrik; Conradi, Lenard; Zierer, Andreas; Anselmi, Amedeo; Dumonteil, Nicolas; Nickenig, Georg; Piñón, Miguel; Barth, Sebastian; Adamo, Marianna; Dubois, Christophe; Torracca, Lucia; Maisano, Francesco; Lurz, Philipp; von Bardeleben, Ralph Stephan; Hausleiter, Jörg; TENDER Investigators.
In: JACC-CARDIOVASC INTE, Vol. 17, No. 5, 11.03.2024, p. 648-661.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Transapical Mitral Valve Replacement: 1-Year Results of the Real-World Tendyne European Experience Registry
AU - Hell, Michaela M
AU - Wild, Mirjam G
AU - Baldus, Stephan
AU - Rudolph, Tanja
AU - Treede, Hendrik
AU - Petronio, Anna Sonia
AU - Modine, Thomas
AU - Andreas, Martin
AU - Coisne, Augustin
AU - Duncan, Alison
AU - Franco, Luis Nombela
AU - Praz, Fabien
AU - Ruge, Hendrik
AU - Conradi, Lenard
AU - Zierer, Andreas
AU - Anselmi, Amedeo
AU - Dumonteil, Nicolas
AU - Nickenig, Georg
AU - Piñón, Miguel
AU - Barth, Sebastian
AU - Adamo, Marianna
AU - Dubois, Christophe
AU - Torracca, Lucia
AU - Maisano, Francesco
AU - Lurz, Philipp
AU - von Bardeleben, Ralph Stephan
AU - Hausleiter, Jörg
AU - TENDER Investigators
N1 - Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2024/3/11
Y1 - 2024/3/11
N2 - BACKGROUND: Early studies of the Tendyne transcatheter mitral valve replacement (TMVR) showed promising results in a small selective cohort.OBJECTIVES: The authors present 1-year data from the currently largest commercial, real-world cohort originating from the investigator-initiated TENDER (Tendyne European Experience) registry.METHODS: All patients from the TENDER registry eligible for 1-year follow-up were included. The primary safety endpoint was 1-year cardiovascular mortality. Primary performance endpoint was reduction of mitral regurgitation (MR) up to 1 year.RESULTS: Among 195 eligible patients undergoing TMVR (median age 77 years [Q1-Q3: 71-81 years], 60% men, median Society of Thoracic Surgeons Predicted Risk of Mortality 5.6% [Q1-Q3: 3.6%-8.9%], 81% in NYHA functional class III or IV, 94% with MR 3+/4+), 31% had "real-world" indications for TMVR (severe mitral annular calcification, prior mitral valve treatment, or others) outside of the instructions for use. The technical success rate was 95%. The cardiovascular mortality rate was 7% at 30 day and 17% at 1 year (all-cause mortality rates were 9% and 29%, respectively). Reintervention or surgery following discharge was 4%, while rates of heart failure hospitalization reduced from 68% in the preceding year to 25% during 1-year follow-up. Durable MR reduction to ≤1+ was achieved in 98% of patients, and at 1 year, 83% were in NYHA functional class I or II. There was no difference in survival and major adverse events between on-label use and "real-world" indications up to 1 year.CONCLUSIONS: This large, real-world, observational registry reports high technical success, durable and complete MR elimination, significant clinical benefits, and a 1-year cardiovascular mortality rate of 17% after Tendyne TMVR. Outcomes were comparable between on-label use and "real-world" indications, offering a safe and efficacious treatment option for patients without alternative treatments. (Tendyne European Experience Registry [TENDER]; NCT04898335).
AB - BACKGROUND: Early studies of the Tendyne transcatheter mitral valve replacement (TMVR) showed promising results in a small selective cohort.OBJECTIVES: The authors present 1-year data from the currently largest commercial, real-world cohort originating from the investigator-initiated TENDER (Tendyne European Experience) registry.METHODS: All patients from the TENDER registry eligible for 1-year follow-up were included. The primary safety endpoint was 1-year cardiovascular mortality. Primary performance endpoint was reduction of mitral regurgitation (MR) up to 1 year.RESULTS: Among 195 eligible patients undergoing TMVR (median age 77 years [Q1-Q3: 71-81 years], 60% men, median Society of Thoracic Surgeons Predicted Risk of Mortality 5.6% [Q1-Q3: 3.6%-8.9%], 81% in NYHA functional class III or IV, 94% with MR 3+/4+), 31% had "real-world" indications for TMVR (severe mitral annular calcification, prior mitral valve treatment, or others) outside of the instructions for use. The technical success rate was 95%. The cardiovascular mortality rate was 7% at 30 day and 17% at 1 year (all-cause mortality rates were 9% and 29%, respectively). Reintervention or surgery following discharge was 4%, while rates of heart failure hospitalization reduced from 68% in the preceding year to 25% during 1-year follow-up. Durable MR reduction to ≤1+ was achieved in 98% of patients, and at 1 year, 83% were in NYHA functional class I or II. There was no difference in survival and major adverse events between on-label use and "real-world" indications up to 1 year.CONCLUSIONS: This large, real-world, observational registry reports high technical success, durable and complete MR elimination, significant clinical benefits, and a 1-year cardiovascular mortality rate of 17% after Tendyne TMVR. Outcomes were comparable between on-label use and "real-world" indications, offering a safe and efficacious treatment option for patients without alternative treatments. (Tendyne European Experience Registry [TENDER]; NCT04898335).
U2 - 10.1016/j.jcin.2023.12.027
DO - 10.1016/j.jcin.2023.12.027
M3 - SCORING: Journal article
C2 - 38385922
VL - 17
SP - 648
EP - 661
JO - JACC-CARDIOVASC INTE
JF - JACC-CARDIOVASC INTE
SN - 1936-8798
IS - 5
ER -
